Chris Emery has joined OpGen as Chief Commercial Officer: Americas after serving as President and CEO of Curetis USA, Inc., bringing more than 20 years of healthcare experience and 10 years in executive leadership roles in the laboratory diagnostics, medical device and pharmaceuticals industries.
Chris’ primary focus has been leading the commercial launch and execution for numerous next-generation molecular diagnostic assays in the precision medicine market. Most recently, he was the Chief Commercial Officer – North America for Menarini Silicon Biosystems, where he directed the U.S. sales and business development activities for the DEPArray NxT molecular device as well as the integration of the FDA-cleared CellSearch Circulating Tumor Cell assay. Prior, Chris was the General Manager for Abbott’s PersonalizeDx cancer diagnostics laboratory division, and he also held senior level management roles as Chief Operating Officer at CombiMatrix, and National Sales & Marketing Manager at US LABS, prior to its acquisition by LabCorp. Chris began his career in healthcare with Johnson & Johnson, promoting the antibiotic Levaquin into hospital systems for a wide variety of bacterial infections, including Hospital-Acquired Pneumonia and complicated Urinary Tract Infections.
He obtained his MBA from Pepperdine University and his BA in Communications Studies from University of California – San Diego.